StreetInsider.com News Articles

Form 8-K Lantheus Holdings, Inc. For: Oct 14

Wed, 14 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261014/27187507.html

Mizuho Downgrades Lantheus Holdings (LNTH) to Neutral

Tue, 13 Oct 2026 06:56:22 -0400

Mizuho analyst Anthony Petrone downgraded Lantheus Holdings (NASDAQ: LNTH) from Outperform to Neutral.

For an analyst ratings summary and ratings history on Lantheus Holdings click here. For more ratings news on Lantheus Holdings click here.

Shares of Lantheus Holdings closed at $100.11 yesterday.

Form DEFA14A Lantheus Holdings, Inc.

Fri, 02 Oct 2026 17:02:00 -0400

si-local-file:///var/storage/secattach/20261002/27143356.html

Form 8-K Lantheus Holdings, Inc. For: Oct 02

Fri, 02 Oct 2026 17:01:00 -0400

si-local-file:///var/storage/secattach/20261002/27143327.html

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Wed, 30 Sep 2026 08:30:00 -0400

Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent

BEDFORD, Mass., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the Centers for Medicare & Medicaid Services (“CMS”) has granted Transitional Pass-Through (“TPT”) payment status for PYLARIFY^® TruVu™ (piflufolastat F18) injection, effective October 1, 2026. The designation enables separate reimbursement for PYLARIFY TruVu in the

Lantheus Announces CMS Grants Transitional Pass-Through Status for PYLARIFY® TruVu (piflufolastat F 18)

Wed, 30 Sep 2026 08:30:00 -0400

Designation, together with a permanent HCPCS code effective October 1, 2026, supports patient access and reimbursement for PYLARIFY TruVu, Lantheus' PSMA PET imaging agent

Lantheus doses first patient in SPARROW prostate cancer imaging trial

Mon, 28 Sep 2026 08:00:28 -0400

Lantheus Holdings (NASDAQ: LNTH) announced that the first patient has been dosed in SPARROW, a Phase 2/3 registrational trial evaluating LNTH-2401, an investigational gallium-68-labeled positron emission tomography (PET) imaging agent that targets the gastrin-releasing peptide receptor (GRPR).

GRPR is a biomarker expressed in many primary prostate cancers and has a distinct biological expression pattern from prostate-specific membrane antigen (PSMA). The first patient was dosed at BAMF Health, one of the trial's participating sites.

SPARROW is an open-label, non-randomized, multicenter study structured in two periods. The Phase 2 portion will enroll up to 12 participants with newly diagnosed or biochemically recurrent prostate cancer

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Mon, 28 Sep 2026 08:00:00 -0400

Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer

BEDFORD, Mass., Sept. 28, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the first patient has been dosed in SPARROW NCT07831824, a Phase 2/3 registrational trial evaluating LNTH-2401 (⁶⁸Ga-DOTA-RM2). LNTH-2401 is an investigational gallium-68-labeled positron emission tomography (PET) imaging agent that targets the gastrin-releasing peptide receptor (GRPR), a biomarker that is highly expressed in many prostate

Lantheus Announces First Patient Dosed in SPARROW Phase 2/3 Registrational Trial in Prostate Cancer

Mon, 28 Sep 2026 08:00:00 -0400

Study advances development of Lantheus' investigational GRPR-targeted PET imaging program for prostate cancer

FDA approves Lantheus' Bravnetsa as equivalent to Lutathera for GEP-NETs

Tue, 22 Sep 2026 08:01:04 -0400

Lantheus Holdings (NASDAQ: LNTH) announced that the U.S. Food and Drug Administration has granted final approval for Bravnetsa (lutetium Lu 177 dotatate), a radiopharmaceutical indicated for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs), including foregut, midgut, and hindgut neuroendocrine tumors.

The FDA determined Bravnetsa to be bioequivalent and therapeutically equivalent to Lutathera (lutetium Lu 177 dotatate), a product of Advanced Accelerator Applications USA Inc., a Novartis company. Lantheus states Bravnetsa is the only radiopharmaceutical the FDA has made such a determination for relative to Lutathera.

Bravnetsa was approved through the FDA's Abbreviated New Drug Application (ANDA) pathway.

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for

Tue, 22 Sep 2026 08:00:00 -0400

Approval of BRAVNETSA expands radioligand treatment options for adult patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

BEDFORD, Mass., Sept. 22, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. ("Lantheus" or the "Company") (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced that the U.S. Food and Drug Administration (FDA) has granted final approval for BRAVNETSA™ (lutetium Lu 177 dotatate), a bioequivalent and therapeutically equivalent radiopharmaceutical to LUTATHERA^® (lutetium Lu 177 dotatate). BRAVNETSA is indicated for the treatment of adult patients with somatostatin receptor-positive gastroenteropancreatic

Lantheus Receives Final FDA Approval for BRAVNETSA™ (Lutetium Lu 177 Dotatate), the Only Radiopharmaceutical FDA has Determined to be Bioequivalent and Therapeutically Equivalent to LUTATHERA® for

Tue, 22 Sep 2026 08:00:00 -0400

Approval of BRAVNETSA expands radioligand treatment options for adult patients with somatostatin receptor-positive (SSTR+) gastroenteropancreatic neuroendocrine tumors (GEP-NETs)

Form DEFA14A Lantheus Holdings, Inc.

Mon, 21 Sep 2026 16:08:00 -0400

si-local-file:///var/storage/secattach/20260921/27085413.html

Form 8-K Lantheus Holdings, Inc. For: Sep 17

Mon, 21 Sep 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20260921/27085381.html

Form DEFA14A Lantheus Holdings, Inc.

Thu, 17 Sep 2026 06:02:00 -0400

si-local-file:///var/storage/secattach/20260917/27072280.html

Form PREM14A Lantheus Holdings, Inc. For: Aug 26

Wed, 26 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260826/26977279.html

Form PREM14A Lantheus Holdings, Inc. For: Aug 26

Wed, 26 Aug 2026 07:20:00 -0400

si-local-file:///var/storage/secattach/20260826/26977279.html

Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Dinkelborg Ludger

Wed, 19 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260819/26950574.html

Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Dinkelborg Ludger

Wed, 19 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260819/26950574.html

Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Brown Kimberly

Wed, 19 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260819/26950571.html

Form 4 Lantheus Holdings, Inc. For: Aug 17 Filed by: Brown Kimberly

Wed, 19 Aug 2026 16:34:00 -0400

si-local-file:///var/storage/secattach/20260819/26950571.html

B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral

Mon, 17 Aug 2026 12:16:40 -0400

B.Riley analyst Justin Walsh downgraded Lantheus Holdings (NASDAQ: LNTH) from Buy to Neutral with a price target of $105.40 (from $129.00).

The analyst comments "Curium will acquire Lantheus Holdings, Inc. (LNTH — Buy, $105.40 PT) for $102.50/sh plus up to $12/sh in CVRs for 2030 milestones, with a closing in 1H27, against a May 2, 2027, outside date. We believe three overlaps exist: 1) Detectnet (Curium) vs. OCTEVY in NET imaging; 2) Cu64- PSMA-I&T (Curium) vs. Pylarify TruVu, and 3) Lu177 dotatate vs. PNT2003, both of which are generic versions of Lutathera. According to the AGREEMENT AND PLAN OF MERGER, Curium

B.Riley Downgrades Lantheus Holdings (LNTH) to Neutral

Mon, 17 Aug 2026 12:16:40 -0400

B.Riley analyst Justin Walsh downgraded Lantheus Holdings (NASDAQ: LNTH) from Buy to Neutral with a price target of $105.40 (from $129.00).

FDA approves Lantheus tau PET imaging agent for Alzheimer's disease

Fri, 14 Aug 2026 08:00:31 -0400

Lantheus Holdings (NASDAQ: LNTH) announced that the U.S. Food and Drug Administration has approved TAUKLARIFY (florquinitau F 18 injection), a radiodiagnostic agent for positron emission tomography imaging of the brain in adults with cognitive impairment being evaluated for Alzheimer's disease.

The agent, also referred to as MK-6240, is indicated to identify patients with tau neurofibrillary tangle pathology. The FDA has noted a limitation of use: the safety and effectiveness of TAUKLARIFY have not been established for the evaluation of non-Alzheimer's disease tauopathies.

The approval is supported by two blinded read studies analyzing PET images from more than 500 subjects across three clinical

Lantheus Announces FDA Approval of TAUKLARIFY™ (Florquinitau F 18 Injection), an F18-Labeled Tau PET Imaging Agent for Alzheimer’s Disease

Fri, 14 Aug 2026 08:00:00 -0400

BEDFORD, Mass., Aug. 14, 2026 (GLOBE NEWSWIRE) -- Lantheus Holdings, Inc. (“Lantheus” or the “Company”) (NASDAQ: LNTH), the leading radiopharmaceutical-focused company committed to enabling clinicians to Find, Fight and Follow disease to deliver better patient outcomes, today announced U.S. Food and Drug Administration (FDA) approval of TAUKLARIFY™ (florquinitau F 18 injection), also referred to as MK-6240, a radiodiagnostic agent indicated for positron emission tomography (PET) of the brain in adults with cognitive impairment who are being evaluated for Alzheimer’s disease to identify patients with tau neurofibrillary tangle (NFT) pathology. TAUKLARIFY has a limitation of use. The safety and